Ownership history in Meditor Group Ltd · 30 quarters on record
This page tracks every 13F SEC filing in which Meditor Group Ltd reported a position in ESPERION THERAPEUTICS INC (ESPR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2024 Q3 | UNCHANGED | 3,791,300 | — | 0% | 12.99% | $6.3M | $1.65 |
| 2024 Q2 | UNCHANGED | 3,791,300 | — | 0% | 15.57% | $8.4M | $2.22 |
| 2024 Q1 | UNCHANGED | 3,791,300 | — | 0% | 14.93% | $10.2M | $2.68 |
| 2023 Q4 | UNCHANGED | 3,791,300 | — | 0% | 14.17% | $11.3M | $2.99 |
| 2023 Q3 | REDUCED | 3,791,300 | -611,673 | -13.9% | 4.82% | $3.7M | $0.98 |
| 2023 Q2 | UNCHANGED | 4,402,973 | — | 0% | 5.31% | $6.1M | $1.39 |
| 2023 Q1 | REDUCED | 4,402,973 | -65,862 | -1.5% | 5.58% | $7.0M | $1.59 |
| 2022 Q4 | UNCHANGED | 4,468,835 | — | 0% | 18.82% | $27.8M | $6.23 |
| 2022 Q3 | UNCHANGED | 4,468,835 | — | 0% | 19.92% | $29.9M | $6.70 |
| 2022 Q2 | UNCHANGED | 4,468,835 | — | 0% | 14.05% | $28.4M | $6.36 |
As of 2025 Q4 — sorted by position size